By Illana Goldfinger, Life Sciences practice group leader
While many brokers lament the “soft market” and excess capacity across most commercial lines, the picture looks quite different in Life Sciences, especially in biotech. D&O premiums continue to climb, and markets willing to take on this class of risk are shrinking. So, what’s driving this trend?
When a “miss” means something different
The simplest way to understand why insurers are pulling back is to look at what “missing” means in biotech versus in tech.
For a SaaS company, missing a quarterly target is inconvenient but survivable. They can pivot—adjust pricing, add features, shift marketing—and hold tight until growth picks up.
For a biotech firm, however, a failed clinical trial can erase 70% of market capitalization overnight. That kind of event creates an immediate and severe litigation profile. Lawsuits follow quickly, not because fraud is proven, but because disclosure is questioned. Shareholders only need the suggestion of misrepresentation to file claims. Insurers know this, and they price accordingly.
Where science meets securities
When a Phase II trial misses its milestones, the problem doesn’t end in the lab. Investors, shareholders and regulators begin asking questions: Were the risks clearly communicated? Were adverse signals minimized? Did management overstate success probabilities?
At this point, the scrutiny shifts from the science to the securities. Biotech companies operate under dual accountability: the FDA for scientific integrity and the SEC for market transparency. D&O insurers analyze risk right at that intersection of science and governance.
Biotech optimism meets underwriting realism
Biotech thrives on optimism. It’s the belief that today’s research could reshape medicine tomorrow. Insurance, however, operates on actuarial realism: numbers, loss data and probability.
This creates a natural tension. Underwriters ask: How is the company positioned financially? Why are there repeated large losses? What is the burn rate? Meanwhile, biotech companies must project optimism to secure funding. That optimism is essential, but capital markets and regulators price on disclosure, accuracy and governance discipline, not hope.
The aftermath of the biotech SPAC wave
The SPAC wave brought a surge of early-stage biotech companies into the public markets. Many were pre-revenue, still run like venture-funded R&D organizations. When timelines slipped and milestones missed, the public markets reacted harshly. Share prices fell, capital tightened and securities litigation soon followed.
Insurers reacted to this volatility. The higher premiums we’re seeing today are, in part, a market response to the governance challenges revealed by that wave.
Governance hasn’t caught up to the science
While biotech science has advanced rapidly – gene editing, mRNA platforms, AI-driven protein design – governance practices haven’t evolved at the same pace.
Boards are often filled with brilliant scientists and investors, but not always seasoned public-company operators. Underwriters evaluate that gap carefully. They assess board independence, financial controls, disclosure practices, management experience and litigation history across the sector. Weakness in any of these areas increases perceived governance risk – and cost.
D&O insurance as a governance audit
D&O insurance isn’t just protection; it’s a governance audit conducted by the insurance markets. When premiums rise, it’s worth asking not just “Why is this so high?” but “What does this tell us about how the company is governed?”
Experienced boards, careful disclosures and disciplined communication all influence how the insurance market perceives risk. D&O underwriters aren’t emotional, they’re analytical. Their pricing reflects the data story of governance, not sentiment.
From scientific risk to governance risk
Biotech has always understood scientific risk. What it’s still adapting to is governance risk – the reputational and disclosure hazards that come with operating in public markets.
D&O premiums aren’t rising because insurers have lost confidence in innovation; they’re rising because carriers now have sufficient data to quantify behavior patterns: volatility, litigation frequency, disclosure missteps and governance growing pains in a fast-evolving field.
What rising premiums are telling boards
Insurance markets are often the first to formalize what others only sense informally. When premiums rise and capacity tightens, it’s not arbitrary, it’s actuarial feedback.
For founders and boards, the right response isn’t frustration at the price, but introspection about what it reflects. Are disclosure controls as strong as the science? Is the board composition suitable for public market scrutiny? Is optimism balanced with accuracy?
Today, governance discipline isn’t a back-office process, it’s part of strategic infrastructure.
Pricing as a read on risk culture
D&O insurance may appear to be just another line item, but it’s also one of the clearest external signals of how the market perceives a company’s risk culture. In biotech, that culture of how a company manages uncertainty, communicates risk and governs transparency is as critical to investor confidence as the next scientific breakthrough.
